Literature DB >> 10867515

Fas-Fas ligand system in the peripheral blood of patients with renal diseases.

M Sato1, T Konuma, N Yanagisawa, H Haizuka, H Asakura, Y Nakashima.   

Abstract

To clarify the role of the Fas-Fas ligand (FasL) system in the peripheral blood from patients with various renal diseases, the Fas and FasL expression on mononuclear cells (MNCs) and serum levels of soluble Fas (sFas) and soluble FasL were investigated. Patients were selected from those with various types of glomerular diseases showing various degrees of renal function. Fas expression on MNCs was analyzed by a FACScan, sFas and soluble FasL were measured with an ELISA kit, and FasL expression on MNCs was counted using a FACScan after a bioassay. Fas-positive MNCs and sFas increased with statistical significance concomitantly with deterioration in renal function. Moreover, there was a significant correlation between them. sFas- and FasL-positive MNCs were significantly correlated with proteinuria. However, the Fas expression percentage on MNCs and/or serum levels of sFas did not correlate with the number of TUNEL-positive cells in the glomeruli. Also, there was no disease specificity in the activation of Fas. These results indicate that Fas expression on MNCs is activated in accordance with the deterioration in renal function without disease specificity, corresponding to the elevation of serum sFas levels to protect against Fas-mediated apoptosis. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10867515     DOI: 10.1159/000045642

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  5 in total

1.  Glomerular expression and elevated serum Bcl-2 and Fas proteins in lupus nephritis: preliminary findings.

Authors:  N A Fathi; M R Hussein; H I Hassan; E Mosad; H Galal; N A Afifi
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

2.  Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney disease.

Authors:  Kevin S Heffernan; Jeffrey T Kuvin; Mark J Sarnak; Ronald D Perrone; Dana C Miskulin; Darya Rudym; Priya Chandra; Richard H Karas; Vandana Menon
Journal:  Nephrol Dial Transplant       Date:  2011-02-03       Impact factor: 5.992

3.  Serum sFAS levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases.

Authors:  Marta Christensson; Erna Pettersson; Kjell Eneslätt; Birger Christensson; Johan Bratt; Solbritt Rantapää-Dahlqvist; Karl-Gösta Sundqvist
Journal:  J Clin Immunol       Date:  2002-07       Impact factor: 8.317

4.  S-Fas urinary excretion helps to predict the immunosuppressive treatment outcomes in patients with proliferative primary glomerulonephritis.

Authors:  Rafał Zwiech
Journal:  J Korean Med Sci       Date:  2013-09-25       Impact factor: 2.153

5.  Impact of Continuous Erythropoietin Receptor Activator on Selected Biomarkers of Cardiovascular Disease and Left Ventricle Structure and Function in Chronic Kidney Disease.

Authors:  Piotr Bartnicki; Jacek Rysz; Beata Franczyk; Zbigniew Baj; Ewa Majewska
Journal:  Oxid Med Cell Longev       Date:  2016-02-29       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.